Abstract:
Newcastle disease is the most important disease next to avian influenza which causes high morbidity and mortality resulting in huge economic loss to poultry industry. Vaccination is the best way to control many infectious diseases. Currently available live attenuated and killed vaccines for Newcastle disease require cold chain maintenance. In the third world countries cold chain maintenance is cumbersome. To overcome this problem, recombinant protein vaccine delivered through biodegradable polylactic-co-glycolic acid (PLGA) nanoparticles offers a promising opportunity in vaccine technology.
Poly (lactic-co-glycolic acid) (PLGA) is a biocompatible member of the aliphatic polyester family of biodegradable polymers. PLGA has long been a popular choice for drug delivery applications, particularly; it is already FDA-approved for use in humans in the form of resorbable sutures.
Polylactide-co-glycolic acid (PLGA) nanoparticles were synthesized by Double emulsion solvent evaporation method. The size of the PLGA nanoparticles measured in the scanning electron microscopy (SEM) was 280- 320 nm. The polydispersity index (PDI) of PLGA nanoparticles was 0.192. Zeta potential of the PLGA nanoparticles was -2.61 mV. The protein release was determined by in vitro using Bradford assay. It showed consistent protein release was observed every 24 hrs interval.
|
